- |||||||||| uliledlimab (TJD5) - I / Mab, Tracon Pharma
Integrated PK/PD Modeling for Uliledlimab, an Anti-CD73 Monoclonal Antibody, In Non-Small Cell Lung Cancer Patients (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1155;
The K-M analysis indicated that the uliledlimab C trough threshold of 80 ?g/mL may be associated with PFS benefit and is likely clinically meaningful. The non-traditional integrated PK/PD coupled with modeling & simulation and exposure-response analyses and findings support and inform further uliledlimab development in NSCLC patients.
- |||||||||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, uliledlimab (TJD5) - I / Mab, Tracon Pharma
Enrollment closed, IO biomarker, Metastases: A Phase I/II Study of TJ004309 for Advanced Solid Tumor (clinicaltrials.gov) - Apr 15, 2024
P1/2, N=376, Active, not recruiting,
The non-traditional integrated PK/PD coupled with modeling & simulation and exposure-response analyses and findings support and inform further uliledlimab development in NSCLC patients. Recruiting --> Active, not recruiting
- |||||||||| uliledlimab (TJD5) - I / Mab, Tracon Pharma
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ (clinicaltrials.gov) - Oct 12, 2023
P2, N=25, Completed,
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Feb 2023 | Trial primary completion date: Jun 2023 --> Feb 2023
- |||||||||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, uliledlimab (TJD5) - I / Mab, Tracon Pharma
Trial completion date, Trial primary completion date, IO biomarker, Metastases: A Phase I/II Study of TJ004309 for Advanced Solid Tumor (clinicaltrials.gov) - Mar 14, 2023
P1/2, N=376, Recruiting,
Uliledlimab and toripalimab combination therapy was well-tolerated in treatment na Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| uliledlimab (TJD5) - I / Mab, Tracon Pharma
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ (clinicaltrials.gov) - Nov 15, 2022
P2, N=25, Active, not recruiting,
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Recruiting --> Active, not recruiting | N=60 --> 25 | Trial completion date: Jan 2025 --> Jun 2023 | Trial primary completion date: Oct 2024 --> Jun 2023
- |||||||||| uliledlimab (TJD5) - I / Mab, Tracon Pharma
Revealing Novel Therapeutic Indications through Profiling of Immune Modulatory Properties by Uliledlimab (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1459;
Conclusions Our study has delineated the immune regulatory properties of uliledlimab as evident by its down-regulation of immuno-suppressive pathways and restored activity of cytolysis and phagocytosis of various effector cells. In addition to the current combination therapy of uliledlimab with PD-L1 inhibitor, identification of selected pathways regulated by uliledlimab and their co-expression with CD73 that serves as a negative prognosis factor provides much needed scientific rationale to explore new combination therapies of uliledlimab in cancers.
- |||||||||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, uliledlimab (TJD5) - I / Mab, Tracon Pharma
Enrollment change, IO biomarker, Metastases: A Phase I/II Study of TJ004309 for Advanced Solid Tumor (clinicaltrials.gov) - Aug 4, 2022
P1/2, N=376, Recruiting,
In addition to the current combination therapy of uliledlimab with PD-L1 inhibitor, identification of selected pathways regulated by uliledlimab and their co-expression with CD73 that serves as a negative prognosis factor provides much needed scientific rationale to explore new combination therapies of uliledlimab in cancers. N=221 --> 376
- |||||||||| uliledlimab (TJD5) - I / Mab, Tracon Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of TJ004309 in Combination With Atezolizumab (Tecentriq (clinicaltrials.gov) - Apr 1, 2022
P1, N=36, Active, not recruiting,
Full saturation of circulating and cell-bound CD73 was maintained at doses ≥ 15 mg/kg Q3W. Trial completion date: Mar 2022 --> Jun 2022 | Trial primary completion date: Feb 2022 --> Jun 2022
- |||||||||| uliledlimab (TJD5) - I / Mab, Tracon Pharma
Enrollment open, Combination therapy, Metastases: A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ (clinicaltrials.gov) - Feb 2, 2022
P2, N=60, Recruiting,
Trial completion date: Mar 2022 --> Jun 2022 | Trial primary completion date: Feb 2022 --> Jun 2022 Not yet recruiting --> Recruiting
- |||||||||| uliledlimab (TJD5) - I / Mab, Tracon Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of TJ004309 in Combination With Atezolizumab (Tecentriq (clinicaltrials.gov) - Nov 4, 2021
P1, N=36, Active, not recruiting,
Not yet recruiting --> Recruiting Trial completion date: Sep 2021 --> Jan 2022 | Trial primary completion date: Sep 2021 --> Jan 2022
- |||||||||| uliledlimab (TJD5) - I / Mab, Tracon Pharma
Trial primary completion date, Combination therapy, Metastases: Study of TJ004309 in Combination With Atezolizumab (Tecentriq (clinicaltrials.gov) - Sep 9, 2021
P1, N=36, Active, not recruiting,
Trial completion date: Sep 2021 --> Jan 2022 | Trial primary completion date: Sep 2021 --> Jan 2022 Trial primary completion date: Jun 2021 --> Sep 2021
- |||||||||| uliledlimab (TJD5) - I / Mab, Tracon Pharma
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Study of TJ004309 in Combination With Atezolizumab (Tecentriq (clinicaltrials.gov) - May 6, 2021
P1, N=36, Active, not recruiting,
Trial primary completion date: Jun 2021 --> Sep 2021 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2021 --> Jun 2021
- |||||||||| uliledlimab (TJD5) - I / Mab, Tracon Pharma
[VIRTUAL] A differentiated CD73 blocking antibody with a unique intra-dimer binding mechanism for cancer immunotherapy () - Mar 11, 2021 - Abstract #AACR2021AACR_3319;
TJD5 is a humanized anti-CD73 antibody with a unique C-terminal domain epitope that enables a novel intra-dimer binding mode, which strongly differentiates it from other CD73 antibodies both in terms of mechanism of action and inhibitory potency. TJD5 is now in phase I clinical development both in the US and China to validate these differentiated properties and anti-tumor activity.
- |||||||||| uliledlimab (TJD5) - I / Mab, Tracon Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of TJ004309 in Combination With Atezolizumab (Tecentriq (clinicaltrials.gov) - Aug 17, 2020
P1, N=36, Recruiting,
TJD5 is now in phase I clinical development both in the US and China to validate these differentiated properties and anti-tumor activity. Trial completion date: Jan 2021 --> Sep 2021 | Trial primary completion date: Jul 2020 --> Dec 2020
- |||||||||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, uliledlimab (TJD5) - I / Mab, Tracon Pharma
Enrollment status, PD(L)-1 Biomarker, IO biomarker, Metastases: A Phase I/II Study of TJ004309 for Advanced Solid Tumor (clinicaltrials.gov) - Jun 11, 2020
P1/2, N=221, Recruiting,
Trial completion date: Jan 2021 --> Sep 2021 | Trial primary completion date: Jul 2020 --> Dec 2020 Enrolling by invitation --> Recruiting
- |||||||||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, uliledlimab (TJD5) - I / Mab, Tracon Pharma
Enrollment open, PD(L)-1 Biomarker, IO biomarker, Metastases: A Phase I/II Study of TJ004309 for Advanced Solid Tumor (clinicaltrials.gov) - May 21, 2020
P1/2, N=221, Enrolling by invitation,
Enrolling by invitation --> Recruiting Not yet recruiting --> Enrolling by invitation
- |||||||||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, uliledlimab (TJD5) - I / Mab, Tracon Pharma
New P1/2 trial, PD(L)-1 Biomarker, IO biomarker, Metastases: A Phase I/II Study of TJ004309 for Advanced Solid Tumor (clinicaltrials.gov) - Mar 25, 2020
P1/2, N=221, Not yet recruiting,
- |||||||||| uliledlimab (TJD5) - I / Mab, Tracon Pharma
Trial primary completion date, Combination therapy, Metastases: Study of TJ004309 in Combination With Atezolizumab (Tecentriq (clinicaltrials.gov) - Mar 2, 2020
P1, N=36, Recruiting,
Not yet recruiting --> Enrolling by invitation Trial primary completion date: Mar 2020 --> Jul 2020
- |||||||||| uliledlimab (TJD5) - I / Mab, Tracon Pharma
Enrollment open, Combination therapy, Metastases: Study of TJ004309 in Combination With Atezolizumab (Tecentriq (clinicaltrials.gov) - Apr 18, 2019
P1, N=36, Recruiting,
Trial primary completion date: Mar 2020 --> Jul 2020 Not yet recruiting --> Recruiting
|
